NO2014032I2 - Kombinasjon av rilpivirin eller et farmasøytisk akseptabelt salt av rilpivirin, medregnet hydrokloridsaltet av rilpivirin, emtricitabin og tenofovir, spesielt tenofovir disoproksil eller tenofovirdisoproksilfumarat. - Google Patents

Kombinasjon av rilpivirin eller et farmasøytisk akseptabelt salt av rilpivirin, medregnet hydrokloridsaltet av rilpivirin, emtricitabin og tenofovir, spesielt tenofovir disoproksil eller tenofovirdisoproksilfumarat.

Info

Publication number: NO2014032I2
Authority: NO; Norway
Prior art keywords: rilpivirine; tenofovir; tenofovir disoproxil; emtricitabine; pharmaceutically acceptable
Prior art date: 2003-09-03

Application number

NO2014032C

Other languages

English (en)

Other versions

NO2014032I1 (no

Original Assignee

Janssen Sciences Ireland Uc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2014-12-18

Publication date

2014-12-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2014032(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-18 Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc

2014-12-18 Publication of NO2014032I2 publication Critical patent/NO2014032I2/no

2015-01-05 Publication of NO2014032I1 publication Critical patent/NO2014032I1/no

Links

YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title 3
229960002814 rilpivirine Drugs 0.000 title 3
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 title 1
VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
229960001355 tenofovir disoproxil Drugs 0.000 title 1
JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 title 1
229960004693 tenofovir disoproxil fumarate Drugs 0.000 title 1
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

NO2014032C 2003-09-03 2014-12-18 (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine. NO2014032I1 (no)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US49977103P	2003-09-03	2003-09-03
EP03103275		2003-09-03
EP03103319		2003-09-08
EP03103335		2003-09-10
EP03103668		2003-10-02
US50848603P	2003-10-03	2003-10-03

Publications (2)

Publication Number	Publication Date
NO2014032I2 true NO2014032I2 (no)	2014-12-18
NO2014032I1 NO2014032I1 (no)	2015-01-05

Family

ID=34280181

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
NO20061374A NO334877B1 (no)	2003-09-03	2006-03-27	Kombinasjoner av et pyrimidin inneholdende NNRTI med RT-inhibitorer
NO2014030C NO2014030I1 (no)	2003-09-03	2014-12-18	(E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.
NO2014032C NO2014032I1 (no)	2003-09-03	2014-12-18	(E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine.
NO2014031C NO2014031I1 (no)	2003-09-03	2014-12-18	(E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino-2-pyrimidinyl]-amino]-benzonitril (Rilpivirie) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpiverine innbefattende hydrokloridsaltet av Rilpivirine, og Temofovir disproksil (spesielt Tenofovir disproksil fumaratsalt).
NO2016026C NO2016026I1 (no)	2003-09-03	2016-12-20	Kombinasjon av rilpivirine eller en terapeutisk ekvivalent form derav så som et farmasøytisk akseptabelt salt av rilpivirine innbefattende hydrokloridsaltet av rilpivirine samt emtricitabine samt tenofovir alafenamid eller et farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamid fumarat
NO2016025C NO2016025I1 (no)	2003-09-03	2016-12-20

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
NO20061374A NO334877B1 (no)	2003-09-03	2006-03-27	Kombinasjoner av et pyrimidin inneholdende NNRTI med RT-inhibitorer
NO2014030C NO2014030I1 (no)	2003-09-03	2014-12-18	(E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]-amino]-2-pyrimidinyl]-amino]-benzonitril("Rilpivirine") samt enhver terapeutisk form derav som er dekket av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpivirie innbefattende hydrokloridsaltet av Rilpivirine, og emtricitabine.

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
NO2014031C NO2014031I1 (no)	2003-09-03	2014-12-18	(E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino-2-pyrimidinyl]-amino]-benzonitril (Rilpivirie) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter av Rilpiverine innbefattende hydrokloridsaltet av Rilpivirine, og Temofovir disproksil (spesielt Tenofovir disproksil fumaratsalt).
NO2016026C NO2016026I1 (no)	2003-09-03	2016-12-20	Kombinasjon av rilpivirine eller en terapeutisk ekvivalent form derav så som et farmasøytisk akseptabelt salt av rilpivirine innbefattende hydrokloridsaltet av rilpivirine samt emtricitabine samt tenofovir alafenamid eller et farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamid fumarat
NO2016025C NO2016025I1 (no)	2003-09-03	2016-12-20

Country Status (24)

Country	Link
US (9)	US20080200435A1 (no)
EP (1)	EP1663240B2 (no)
JP (3)	JP5507791B2 (no)
KR (1)	KR20060090658A (no)
CN (1)	CN101060844B (no)
AP (1)	AP2109A (no)
AU (5)	AU2004268390B2 (no)
BE (1)	BE2015C053I2 (no)
CA (1)	CA2537095C (no)
CY (5)	CY2015038I1 (no)
FI (1)	FI1663240T4 (no)
FR (5)	FR15C0072I2 (no)
HR (1)	HRP20150798T4 (no)
HU (5)	HUS1500053I1 (no)
IL (2)	IL173438A (no)
LT (2)	LTPA2016045I1 (no)
LU (3)	LU92853I2 (no)
MX (1)	MXPA06002437A (no)
MY (1)	MY169670A (no)
NL (2)	NL300781I1 (no)
NO (6)	NO334877B1 (no)
NZ (1)	NZ545306A (no)
PL (1)	PL1663240T5 (no)
WO (1)	WO2005021001A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
CN102702111B (zh)	2002-08-09	2014-12-17	詹森药业有限公司	制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
EA015145B1 (ru)	2003-01-14	2011-06-30	Джилид Сайэнс, Инк.	Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
WO2006024667A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
MX2007002594A (es) *	2004-09-02	2007-04-25	Janssen Pharmaceutica Nv	Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
DK1632232T6 (da) *	2004-09-02	2022-04-19	Janssen Pharmaceutica Nv	Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
UA92467C2 (ru) *	2004-09-02	2010-11-10	Янссен Фармацевтика Н.В.	Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
WO2006024668A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
TWI457136B (zh) *	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en) *	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
US20080317852A1 (en) *	2005-12-14	2008-12-25	Amar Lulla	Pharmaceutical Combination
CA2636436C (en) *	2006-01-20	2014-04-01	Tibotec Pharmaceuticals Ltd.	Long term treatment of hiv- infection with tmc278
US9044509B2 (en)	2006-02-03	2015-06-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr)	2006-07-05	2008-09-26	Univ Aix Marseille Ii	Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) *	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
SG10201408158SA (en)	2008-01-03	2015-03-30	Univ Aix Marseille	Composition and methods used during anti-hiv treatment
CN102711834B (zh) *	2008-12-24	2015-08-26	爱尔兰詹森科学公司	治疗hiv的可植入装置
US8784858B2 (en)	2009-12-21	2014-07-22	Janssen R&D Ireland	Degradable removable implant for the sustained release of an active compound
UA105556C2 (uk)	2010-01-27	2014-05-26	Віів Гелскер Компані	Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
TWI556840B (zh) *	2010-11-19	2016-11-11	吉李德科學股份有限公司	治療用組成物
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
EP2755959B1 (en) *	2011-09-16	2018-05-16	Hetero Research Foundation	Rilpivirine hydrochloride
CA2893843C (en)	2012-12-21	2018-09-04	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
SI3346995T1 (sl)	2015-11-09	2019-11-29	Gilead Sciences Inc	Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
RS65159B1 (sr)	2016-10-24	2024-02-29	Janssen Sciences Ireland Unlimited Co	Disperzibilni sastavi
US20210128554A1 (en) *	2016-12-23	2021-05-06	Temple University - Of The Commonwealth System Of Higher Education	Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
AU2018255954B2 (en) *	2017-04-18	2024-04-04	Cipla Limited	Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) *	2017-07-27	2019-01-31	Cipla Limited	PHARMACEUTICAL COMPOSITIONS
US11166952B2 (en)	2019-11-29	2021-11-09	Aptorum Therapeutics Limited	Composition including rilpivirine and method for treating tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182111A (en) *	1987-11-17	1993-01-26	Boston University Research Foundation	In vivo delivery of active factors by co-cultured cell implants
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5368864A (en) *	1988-11-25	1994-11-29	Henning Berlin Gmbh Chemie- Und Pharmawerk	Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en)	1989-12-22	1994-04-30	The Wellcome Foundation Ltd	Therapeutic nucleosides.
ES2093106T3 (es)	1990-07-19	1996-12-16	Otsuka Pharma Co Ltd	Preparacion solida.
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
CA2121129A1 (en) *	1991-10-29	1993-05-13	Patrick Soon-Shiong	Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1993023021A2 (en)	1992-05-13	1993-11-25	The Wellcome Foundation Limited	Therapeutic combinations
JPH06316524A (ja)	1992-09-11	1994-11-15	Naoyuki Inoue	抗エイズウイルス剤
TW401303B (en)	1994-07-01	2000-08-11	Janssen Pharmaceutica Nv	Anti-HIV triple combination
IT1281502B1 (it) *	1995-06-13	1998-02-18	Sardinian Antiviral Research C	Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
JP2003509453A (ja)	1999-09-21	2003-03-11	アールティーピー・ファーマ・インコーポレーテッド	生物学的に活性な物質の、表面改質された粒状組成物
US6743446B2 (en) *	1999-12-15	2004-06-01	The Ohio State University Research Foundation	Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) *	2000-01-27	2008-01-01	Zentaris Ag	Compressed microparticles for dry injection
BR0109602A (pt)	2000-03-30	2004-06-29	Bristol Myers Squibb Co	Glóbulos de liberação controlada contendo estavudina
US20040115268A1 (en) *	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
DE10050199A1 (de)	2000-10-11	2002-04-25	Ethicon Gmbh	Flächiges Implantat mit im Ultraschall detektierbaren Elementen
CN1487935A (zh)	2000-12-11	2004-04-07	��ҩƷ��ҵ��ʽ��	改良型水溶性药物组合物
MXPA03011784A (es)	2001-06-22	2004-04-02	Pfizer Prod Inc	Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030166509A1 (en)	2001-11-20	2003-09-04	Advanced Inhalation Research, Inc.	Compositions for sustained action product delivery and methods of use thereof
CN102702111B (zh)	2002-08-09	2014-12-17	詹森药业有限公司	制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
AU2003278766A1 (en) *	2002-09-04	2004-03-29	Microchips, Inc.	Method and device for the controlled delivery of parathyroid hormone
AU2003291457A1 (en)	2002-11-08	2004-06-03	Glaxo Group Limited	Pharmaceutical antiviral compositions
AP1927A (en)	2002-11-15	2008-12-10	Tibotec Pharm Ltd	Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en)	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
PL227577B1 (pl)	2003-02-07	2017-12-29	Janssen Pharmaceutica Nv	Zastosowanie pochodnych pirymidyny do wytwarzania leku do zapobiegania zakażeniu wirusem HIV oraz kompozycja farmaceutyczna
KR100629771B1 (ko) *	2004-01-27	2006-09-28	씨제이 주식회사	결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AU2005253957B2 (en)	2004-06-08	2011-08-25	Janssen Pharmaceutica Nv	Pharmaceutical compositions
MY191349A (en)	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DK1632232T6 (da)	2004-09-02	2022-04-19	Janssen Pharmaceutica Nv	Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
WO2006024668A1 (en)	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
AU2005307797B2 (en)	2004-11-16	2011-06-02	Alkermes Pharma Ireland Limited	Injectable nanoparticulate olanzapine formulations
TWI457136B (zh)	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
EP1872390A2 (en) *	2005-04-11	2008-01-02	The Board of Trustees of the Leland Stanford Junior University	Multi-layer structure having a predetermined layer pattern including an agent
AR056652A1 (es)	2005-04-11	2007-10-17	Tibotec Pharm Ltd	Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
EP1893180A2 (en)	2005-06-07	2008-03-05	Pfizer Products Inc.	Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
CN101272848B (zh)	2005-07-28	2013-03-13	Isp投资有限公司	改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
CA2636436C (en)	2006-01-20	2014-04-01	Tibotec Pharmaceuticals Ltd.	Long term treatment of hiv- infection with tmc278
PT2040671T (pt)	2006-06-23	2018-03-14	Janssen Sciences Ireland Uc	Suspensões aquosas de tmc278
US20080081064A1 (en) *	2006-09-28	2008-04-03	Surmodics, Inc.	Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es)	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
US8426434B2 (en)	2007-07-12	2013-04-23	Tibotec Pharmaceuticals Ltd.	Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
US20090123508A1 (en)	2007-10-04	2009-05-14	Boston Scientific Scimed, Inc.	Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
US20110257111A1 (en) *	2008-10-24	2011-10-20	Harbeson Scott L	Hydroxyethlamino Sulfonamide Derivatives

2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en not_active Ceased
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko not_active Ceased
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en not_active Expired
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh not_active Expired - Lifetime
- 2004-09-03 CA CA2537095A patent/CA2537095C/en not_active Expired - Lifetime
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en not_active IP Right Cessation
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja not_active Expired - Lifetime
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/en not_active Expired - Lifetime
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en not_active Expired - Lifetime
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en not_active Expired
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja not_active Expired - Lifetime
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/xx unknown
- 2015-10-20 NL NL300781C patent/NL300781I1/nl unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/xx unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 CY CY2015038C patent/CY2015038I1/el unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 LU LU92854C patent/LU92854I2/xx unknown
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I1/el unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I1/el unknown
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 NO NO2016026C patent/NO2016026I1/no unknown
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 FR FR16C1022C patent/FR16C1022I1/fr active Active
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 FR FR16C1024C patent/FR16C1024I1/fr active Active
- 2016-12-20 CY CY2016049C patent/CY2016049I1/el unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I1/el unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUS1500053I1 (hu)	2016-03-29
EP1663240A1 (en)	2006-06-07
US8841310B2 (en)	2014-09-23
CY2015038I2 (el)	2016-08-31
CY2015040I2 (el)	2016-08-31
US20150283135A1 (en)	2015-10-08
US20140349971A1 (en)	2014-11-27
AU2011201123B2 (en)	2013-10-10
NO2014030I1 (no)	2015-01-05
AU2016210733A1 (en)	2016-08-25
FR15C0073I1 (no)	2015-04-12
NL300768I1 (no)	2015-12-16
FR15C0072I2 (fr)	2019-05-17
JP5820045B2 (ja)	2015-11-24
FR16C1022I1 (fr)	2017-02-03
IL213104A0 (en)	2011-07-31
LU92853I2 (fr)	2015-12-21
FR15C0071I1 (no)	2015-04-12
WO2005021001A1 (en)	2005-03-10
CN101060844A (zh)	2007-10-24
US20100029591A1 (en)	2010-02-04
CY2015040I1 (el)	2016-08-31
NO2014031I2 (no)	2014-12-18
CA2537095C (en)	2012-05-29
CY2016048I2 (el)	2017-07-12
NO2014032I1 (no)	2015-01-05
NO2016025I1 (no)	2016-12-20
CY2015039I2 (el)	2016-08-31
PL1663240T3 (pl)	2015-10-30
US20190216807A1 (en)	2019-07-18
MXPA06002437A (es)	2006-06-20
AP2109A (en)	2010-02-26
FI1663240T4 (fi)	2023-04-25
HK1092698A1 (en)	2007-02-16
NO2014030I2 (no)	2014-12-18
LTPA2016045I1 (lt)	2017-01-10
HRP20150798T4 (hr)	2023-06-09
FR15C0071I2 (fr)	2016-02-12
AU2014203484B2 (en)	2016-09-29
LU92855I2 (fr)	2015-12-21
CY2015038I1 (el)	2016-08-31
KR20060090658A (ko)	2006-08-14
AU2011201123A1 (en)	2011-04-07
AU2019200813A1 (en)	2019-02-28
CN101060844B (zh)	2012-01-04
NO20061374L (no)	2006-03-27
PL1663240T5 (pl)	2024-02-26
NL300781I2 (no)	2016-04-19
US20080200435A1 (en)	2008-08-21
FR16C1024I1 (fr)	2017-02-03
HRP20150798T1 (hr)	2015-09-11
LTC1663240I2 (lt)	2022-05-25
AU2014203484A1 (en)	2014-07-17
LU92854I2 (fr)	2015-12-21
FR15C0073I2 (fr)	2016-02-12
NZ545306A (en)	2009-11-27
AU2004268390B2 (en)	2011-03-31
US20180228800A1 (en)	2018-08-16
AP2006003551A0 (en)	2006-04-30
CY2016049I2 (el)	2017-07-12
LTPA2016044I1 (lt)	2017-01-10
CY2015039I1 (el)	2016-08-31
BE2015C053I2 (no)	2023-12-14
CY2016049I1 (el)	2017-07-12
HUS1600059I1 (hu)	2017-02-28
JP2015044839A (ja)	2015-03-12
AU2004268390A1 (en)	2005-03-10
NO334877B1 (no)	2014-06-23
JP2007520443A (ja)	2007-07-26
JP5507791B2 (ja)	2014-05-28
CY2016048I1 (el)	2017-07-12
EP1663240B1 (en)	2015-04-22
IL173438A (en)	2012-03-29
HUS1500052I1 (hu)	2016-03-29
MY169670A (en)	2019-05-08
NL300781I1 (no)	2016-04-19
EP1663240B2 (en)	2023-03-01
US20200171027A1 (en)	2020-06-04
IL173438A0 (en)	2006-06-11
CA2537095A1 (en)	2005-03-10
NO2014031I1 (no)	2015-01-05
IL213104A (en)	2016-02-29
HUS1600058I1 (hu)	2017-02-28
FR15C0072I1 (no)	2015-04-12
AU2016210733B2 (en)	2018-11-08
NO2016026I1 (no)	2016-12-20
US20220008417A1 (en)	2022-01-13
JP2012051915A (ja)	2012-03-15
HUS1500054I1 (hu)	2016-03-29
NL300768I2 (nl)	2023-08-09
US20170100398A1 (en)	2017-04-13

Legal Events

Date	Code	Title	Description
2015-05-18	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: JANSSEN SCIENCES IRELAND UC, IE

Publication	Publication Date	Title
NO2014030I2 (no)	2014-12-18	en kombinasjon av rilpivirine eller et farmasøytisk akseptabelt salt av rilpivirine innbefattende hydroklorid-saltet av rilpivirine, og emtricitabine.
NO2020007I1 (no)	2020-03-19	Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
NO2023006I1 (no)	2023-02-03	Tenofovir alafenamide or a salt or solvate thereof, especially tenofovir alafenamide fumarate - forlengelse
NO2017047I1 (no)	2017-09-08	Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
NO2018028I2 (no)	2019-01-24	Kombinasjonen alogliptin og pioglitazon, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
NO2017051I1 (no)	2017-10-09	Kariprazin, eventuelt i form av et salt, inkludert kariprazin hydroklorid
TWI347199B (en)	2011-08-21	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
NO20052855D0 (no)	2005-06-13	Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
DK1953162T3 (da)	2012-09-10	Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel.
USD594776S1 (en)	2009-06-23	Abstract human figure
NO2009013I2 (no)	2012-08-27	Laropiprant eller et farmasøytisk akseptabelt saltderav
NO2012009I1 (no)	2012-06-04	Kombinasjonsprodukt av saxaglipin og metformin og farmasøytisk akseptable salter frav, herunder HCI saltene av saxaglipin og metformin
DE60324099D1 (de)	2008-11-27	Arzneistoffhaltiger tampon
IL164249A0 (en)	2005-12-18	Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
SI1562946T1 (sl)	2010-11-30	Novi ksantinski derivati njihova priprava in njihova uporaba kot zdravila
ZA200410015B (en)	2005-09-28	Pharmaceutical salts.
HRP20041157B1 (en)	2012-11-30	Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
ZA200703876B (en)	2008-12-31	2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
NL1024676A1 (nl)	2004-05-06	HIV integrase-remmers, farmaceutische preparaten en methoden voor het gebruik daarvan.
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
ZA200309513B (en)	2004-12-08	Novel heterocyclic derivatives and medicinal use thereof.
MXPA03006249A (es)	2003-09-22	Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
MXPA03008393A (es)	2004-01-29	Derivados de guanidina biciclicos y usos terapeuticos de los mismos.
SI1747201T1 (sl)	2009-04-30	Derivati 2H- ali 3-H-benzo (e)indazol-1-il karbamata, njihova priprava in njihova terapevtska uporaba
RU2002103738A (ru)	2004-03-27	Компонент, обеспечивающий поверхностно-активные свойства композиций-аналогов препаратов для заместительной сурфактантной терапии легочных заболеваний